SLATE-ASSET-MANAGEMENT
15.9.2022 20:01:38 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced a strategic partnership with Roswall Development Inc. (“Roswall”), a fully integrated Canadian renewable energy company based in Halifax, Nova Scotia, through the acquisition of a significant minority stake in the company.
Roswall is an experienced developer of renewable energy projects offering complete energy solutions for infrastructure, industries, and communities in partnership with private and public enterprises. Roswall’s full suite of services includes consulting, strategic planning, design-build installations, development, financing, and operations of renewables projects. The leadership team at Roswall has been active in the renewable energy industry for over 15 years, having successfully developed, constructed, and operated C$150 million of wind, solar, and retrofit projects across North America. Roswall was also awarded the first independent retail electricity licence in Nova Scotia in October 2021.
The partnership with Slate will help fund future renewables projects developed by Roswall, which has a significant and actionable pipeline of wind development opportunities that will support its retail operation by providing 100% clean electricity to its customers. Additionally, it has a growing turnkey business focused on commercial, institutional, and industrial markets. The Roswall team will also benefit from the global expertise, resources, and relationships of the broader Slate platform as it looks to scale its platform across Canada and North America.
“We believe that proven and scalable renewable energy solutions can meaningfully improve the resiliency of our cities and communities by reducing energy consumption, minimizing the environmental impacts of energy production, and increasing the reliability and efficiency of our energy sources,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Roswall’s experienced team has been on the front lines of the significant energy transition taking place globally over the past decade, working to broaden access to affordable, reliable, sustainable, and modern energy sources across North America. We look forward to partnering closely with the Roswall team on integrations across our own real estate portfolio and supporting their mission of continuing to accelerate the energy transition worldwide.”
Daniel Roscoe, Chief Executive Officer at Roswall, said: “The energy economy is changing at a dramatic pace. We have shown with our work in Nova Scotia and the Caribbean that locally produced renewable energy combined with energy retrofits can provide cost savings, emission reductions, and energy security. We are excited to find a likeminded partner in Slate, with the capacity and experience to grow our approach and accelerate energy transition and climate action here in Nova Scotia and abroad.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. The firm recently hired Jeff Rodgers as Managing Director, North American Infrastructure to support the continued growth of Slate’s infrastructure platform globally, with a focus on uncovering investment opportunities tied to the global energy transition in the US and Canada.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.
About Roswall Development Inc.
Roswall Development Inc. is an experienced developer of renewable energy projects, encompassing all aspects from financing and construction to operation. We are focused on enabling regions, industries, and public institutions to become energy self-sufficient through development of renewable energy systems and energy efficiency retrofits. Roswall's team has over 15 years of experience with over $150M of wind, solar and retrofit projects successfully developed, constructed and operated. Active in both Canada and the Caribbean, Roswall is helping accelerate the energy transition by helping companies and institutions get to zero emissions cost effectively. Learn more at roswall.ca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom